ARK Genomic Revolution ETF vs S&P500 ETF — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while S&P500 ETF trades at $752.37. Which is the better fit depends on your goals.
| ARKG | SPY | |
|---|---|---|
Sector | Sector/Thematic | — |
52-Week High | $43.57 | $759.55 |
52-Week Low | $23.09 | $621.75 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
SPY trades at $754.89, up 0.44% with a bullish technical signal from moving averages. The ETF approaches record highs amid AI-driven market enthusiasm, though RSI levels suggest potential overbought conditions. Recent news highlights the S&P 500's strong performance and ongoing sector rotation.
Outlook remains positive with institutional focus on AI infrastructure and earnings growth, but risks include Fed policy uncertainty and stretched valuations. The dividend yield provides income support, with the next payment scheduled for July 2026.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →